Sort   by:  
 Page size 
UnknownPhase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.
Not available
S-EPMC3383119 | biostudies-literature
UnknownPomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study.
Not available
S-EPMC5477825 | biostudies-literature
GenomicsCdx2 Binding Sites On Cdx2 Expressing ES Cells
A) Chromatins were prepared from Cdx2-inducible ES cells cultured for 48 - 60 hours in the Dox+ and Dox- conditions. Chromatin immunoprecipitation (ChIP) was carried out by using anti-FLAG M2 affinity gel. ChIP product was tested by Western blotting using anti-FLAG antibody. Nuclear extract from ES ...
ORGANISM(S): Mus musculus 
2009-10-01 | E-GEOD-14586 | biostudies-arrayexpress
UnknownThe National Lung Screening Trial: overview and study design.
Not available
S-EPMC3009383 | biostudies-literature
UnknownSARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Not available
S-EPMC9762734 | biostudies-literature
UnknownThe global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12687902 | biostudies-literature
UnknownStenting and medical therapy for atherosclerotic renal-artery stenosis.
Not available
S-EPMC4815927 | biostudies-literature
UnknownA Novel Machine Learning Model to Predict Revision ACL Reconstruction Failure in the MARS Cohort.
Not available
S-EPMC11565622 | biostudies-literature
UnknownResidual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury.
Not available
S-EPMC12860639 | biostudies-literature
UnknownPrevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study.
Not available
S-EPMC10005893 | biostudies-literature
Sort   by:  
 Page size